Results 121 to 130 of about 9,051 (207)

Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases. [PDF]

BMJ Med
Rukundo G, Moore M, Semukunzi H, Chatterjee S, Musabyimana JP, Mambo Muvunyi C, Green CA.   +6 more
europepmc   +1 more source

Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda. [PDF]

Nat Microbiol
Tushabe P, Majumdar M, Carlyle S, Shulman L, Ssekagiri A, Joffret ML, Klapsa D, Cremer J, Arowolo KO, Bujaki E, Bukenya H, EPI Laboratory team, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Hawes KM, Bakamutumaho B, Duizer E, Bessaud M, Bandyopadhyay AS, Macadam A, Byabamazima CR, Martin J, Bwogi J.   +46 more
europepmc   +1 more source

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine. [PDF]

Sci Adv
Eshaghi B, Wang EY, Mursalova S, Forster TA, Lasrado N, Tian J, Artzi D, Lin SQ, Wu Z, Yang X, Chung W, Sadeghi I, Garcia J, Chen Z, Sheridan O, Das R, Lau A, Gurram A, Mainou BA, Jones KAV, Liu Y, Barouch DH, von Andrian U, Langer R, Jaklenec A.   +24 more
europepmc   +1 more source

Sub-national modelling of surveillance sensitivity to inform declaration of disease elimination: A retrospective validation against the elimination of wild poliovirus in Nigeria. [PDF]

PLoS Comput Biol
Nightingale ES, Pham-Minh L, Bello IM, Okrior S, Erbeto TB, Baba M, Adeneji A, Auzenbergs M, Edmunds WJ, O'Reilly KM.   +9 more
europepmc   +1 more source

Prevalence and factors associated with non-vaccination: a vaccination coverage survey among children born in Ceará, Brazil, 2017-2018. [PDF]

Rev Soc Bras Med Trop
Maciel AMS, Domingues CMAS, Ferreira AF, França AP, Almeida NMGS, Mota MV, Moraes JC, Ramos AN.   +7 more
europepmc   +1 more source

Coverage and associated factors of inactivated polio vaccine uptake among children aged 12-23 months in Sub-Saharan Africa. [PDF]

Sci Rep
Wondie WT, Zemariam AB, Gebreegziahber ZA, Legesse BT, Belete KT, Mekonnen GB, Gedefaw GD, Atinafu WT, Seifu BL, Tazeb W.   +9 more
europepmc   +1 more source

Navigating change: the ongoing efforts to contain poliovirus in the United States. [PDF]

Front Bioeng Biotechnol
Ottendorfer C, Haynes Smith L, Jorgensen S.   +2 more
europepmc   +1 more source

Oral poliovirus vaccine.

Public health reports (Washington, D.C. : 1896), 1998
openaire   +1 more source

Implementation of Poliovirus Containment in Poliovirus Designated Facilities-United States, 2017-2024. [PDF]

Pathogens
Ottendorfer C, Vander Kelen P, Sanders CA, Watson E, Suppiah S, Hoffman W, Sinclair C, Marfo A, Haynes Smith L.   +8 more
europepmc   +1 more source

Case Report: Infant with vaccine-associated paralytic poliomyelitis unveils global disparities in care for inborn errors of immunity. [PDF]

Front Immunol
Chan CM, Fong ESS, Yeo DYC, Ang EY, Liu IMZ, Ong HT, Chan SM, Chin HL, Yeap FSH, Kee CK, Tan TSZ, Ng NBH, Zhong Y, Lin JB, Wong LSY.   +14 more
europepmc   +1 more source